ID | 1256 |
Name of the vaccine | DTaP-IPVvero |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | up to 49 days |
Description of the vaccine | DTaP-IPV containing IPV produced in a vero-cell line. |
Name of the manufacturer | Statens Serum Institut |
Name of the manufacturing country | Poland |
Year of manufacture | 2006 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Gram-positive bacillus. |
Efficacy | NA |
Vaccine formulation | Solution |
Dosage | 0.5 mL at 2, 3.5, 5 and 16 months of age. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For tetanus, acellular pertussis, and inactivated poliovirus. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (4 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00655148 |
Reference | NA |
Other name | NA |
Additional Links | NA
|